Oxford, UK – 25th October 2017 – OxSonics Limited, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer patients, today announced that Glyn Edwards is to join the board as Non-Executive Director. Glyn Edwards has held the position of CEO of Summit plc since April 2012 where he has restructured the business, taken the company through a NASDAQ listing and focused on its infectious and rare disease clinical development programs. Prior to joining Summit, Mr Edwards served as interim CEO of the BioIndustry Association (BIA), a UK trade organisation, from November 2011 to June 2012, and as CEO at Antisoma plc, a biotechnology company specialising in the development of novel drugs for the treatment of cancer, from 1998 to 2011. Mr Edwards received a BSc in Biochemistry from Bristol University and a MSc in Economics from the London Business School. Mr Edwards was awarded an MBE for his services to the biotechnology industry in 2006.
Dr. Colin Story, Chief Executive Officer commented: “Glyn Edwards brings over four decades of transactional and leadership expertise not just in oncology but also in a range of other therapeutic areas. Glyn is also exceptionally well networked in the industry. I’m very pleased to welcome Glyn to the board at this very exciting time in the company’s history – as we are poised to translate OxSonics drug delivery platform, SonoTran, into clinical use.”
Glyn Edwards commented: “I’m excited to be joining OxSonics at this important point in its development. The company is soon to demonstrate the huge value of the technology and I’m really looking forward to helping OxSonics realise its full potential.”
- ENDS -
About OxSonics™ Limited
OxSonics™ was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics™ SonoTran™ drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran™ can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics™ is based in Oxford, UK. For more information please visit: www.oxsonics.com.